DossierENTITY

Dupixent

Coverage of Dupixent in the Nexus archive.

Earliest in view: Jun 22 · 12:50 UTCMost recent: Jun 22 · 12:50 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 22 · 12:50 UTCQUARTZ
AbbVie is buying an eczema and asthma drug developer for almost $11 billion
AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.